Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
about
Mesothelin is a specific biomarker of invasive cancer in the Barrett-associated adenocarcinoma progression model: translational implications for diagnosis and therapy.Circulating mesothelin protein and cellular antimesothelin immunity in patients with pancreatic cancerMesothelin targeted cancer immunotherapyMolecular therapeutics in pancreas cancerCancer immunotherapy: the beginning of the end of cancer?Viro-immune therapy: A new strategy for treatment of pancreatic cancerCancer immunotherapy for pancreatic cancer utilizing α-gal epitope/natural anti-Gal antibody reactionFueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitorsVaccines for pancreatic cancerCurrent advances in immunotherapy for pancreatic cancerRole of α-gal epitope/anti-Gal antibody reaction in immunotherapy and its clinical application in pancreatic cancerAntigen-specific immunotherapy of cervical and ovarian cancerTyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancerEffect of granulocyte/macrophage colony-stimulating factor on circulating CD8+ and CD4+ T-cell responses to a multipeptide melanoma vaccine: outcome of a multicenter randomized trialA novel human monoclonal antibody that binds with high affinity to mesothelin-expressing cells and kills them by antibody-dependent cell-mediated cytotoxicity.New markers of pancreatic cancer identified through differential gene expression analyses: claudin 18 and annexin A8.Pancreatic cancer.Persistence of donor-derived protein in host myeloid cells after induced rejection of engrafted allogeneic bone marrow cellsHuman antibodies for immunotherapy development generated via a human B cell hybridoma technology.Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma.Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth.Re-adapting T cells for cancer therapy: from mouse models to clinical trials.Pathogenesis of ovarian cancer: clues from selected overexpressed genes.Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma.Mesothelin Immunotherapy for Cancer: Ready for Prime Time?Stromal reengineering to treat pancreas cancerImmunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulationAllogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation.Biological approaches to therapy of pancreatic cancer.Strategies for cancer vaccine development.Chemoimmunotherapy.The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.Preclinical evaluation of MORAb-009, a chimeric antibody targeting tumor-associated mesothelin.Use of tumour-responsive T cells as cancer treatment.Investigational approaches for mesothelioma.Annexin A2 is a new antigenic target for pancreatic cancer immunotherapy.Identification of novel human CTL epitopes and their agonist epitopes of mesothelin.Dendritic-cell-based therapeutic cancer vaccinesEvaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer.GM-CSF gene-modifed cancer cell immunotherapies: of mice and men.
P2860
Q24642374-DA2386D7-CF78-4E95-97C6-FF9C74AFBD43Q24651062-D2998D24-121B-43E1-A965-D4A3ED382BF2Q24656242-1E3FE836-7F05-45E4-84F2-0940E29E365DQ26751709-5FCCBCEA-03D5-4D46-B1EE-F5C912B268ADQ26752277-22F48ECC-7226-490A-9EB4-38BA507DF39FQ26774641-E922C7D2-DDFA-4694-A937-AA2F8D6B6A7FQ26777542-D09B39E2-1B3E-4D92-8F3D-69725274DDE5Q26778793-A4B766E5-D405-4AEC-9A8A-DE34FA62D22FQ26825850-203E93A1-9422-4DAD-96B6-8F60680E26DEQ26830170-69FBE33A-F43D-44A8-BDCA-6B9FAD89B98EQ27024368-01469FC1-1FF5-4922-A87A-73DE098B3DE4Q27488697-51FB7C50-915B-4453-B551-7FB86932AA41Q28740545-3E0763ED-4367-4D9C-8C92-D50346B2F1CCQ30434151-7AC322FB-9920-477B-917E-1A34D0A5FFD1Q30478956-35CFD877-CC88-426D-A69B-8EBDC498B18BQ30489770-66615E0E-C6E7-40D6-9694-B392F9560353Q30490247-93FDB75C-017C-4A0B-B32A-1DEE8CDEC595Q30574633-F917FB15-CA9B-46BD-95EF-0A978B7E0CDBQ33234976-B240A40E-39A7-4861-9C01-4EFE8B930BD0Q33494714-11714ABE-4145-449C-A26F-E35CDE313F6BQ33502208-62D2CFC0-07D0-46E7-919B-7BBAC5568E6AQ33588711-0055F130-4C54-4391-9F7B-D4ED724EAA9EQ33651139-25D56747-2D13-4391-806B-2CC4585A3404Q33776367-F18F46AB-E849-48A0-A3F9-E325520DEB4AQ33816551-DDB6F93B-E682-4BE0-94EC-11A86B9CD2E6Q33827708-2DB5441D-A566-4A67-9797-774C58FD2639Q33848077-6D5BE18A-C4D9-4E22-88DF-BB0F02C7C94DQ33887648-222C3165-859E-424C-A6E3-C0CE56355C76Q33899938-F5B946EE-FDEF-46A5-9FEB-1696B3DF5B42Q34038338-3714E05A-7F20-4B11-ABFB-AFC84F8EB6BCQ34058792-EE533716-8CD7-47D7-A9B2-725ABB4D84FEQ34103645-E4933C45-8F57-4B95-99DE-0323C4076E46Q34111770-6F16EA6F-9B2D-476C-9AA1-04CFD8B6BC9FQ34285656-792739FF-F0CA-4D48-9253-63552FE8DC65Q34293068-29129E8B-3260-4481-B977-B74611AB35D3Q34312466-1D8E1F0F-E5B6-4A23-987E-C6E83A5C3C66Q34313298-80FBB179-4EFA-471C-8301-522AAAB0BA61Q34360094-B106A9B0-331D-417D-BFCA-E7138A8AFAAAQ34362516-F63FA228-EB6D-4890-90EF-FCF929DD4063Q34591128-06B1C4B4-0AC4-44BD-84CA-BA30ED1C4B69
P2860
Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@ast
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@en
type
label
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@ast
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@en
prefLabel
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@ast
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@en
P2093
P2860
P50
P356
P1476
Mesothelin-specific CD8(+) T c ...... ted pancreatic cancer patients
@en
P2093
Amy Morck Thomas
Daniel A Laheru
Eric R Lutz
Lan-Qing Huang
Lynn M Santarsiero
Todd D Armstrong
Yi-Cheng Chen
P2860
P304
P356
10.1084/JEM.20031435
P407
P577
2004-08-01T00:00:00Z